可变剪接在胰腺癌中的研究进展  

Research progress of alternative splicing in pancreatic cancer

作　　者：贺超[1] 曾赟裘 邹彬 黄邵斌 白剑 罗顺添 HE Chao;ZENG Yunqiu;ZOU Bin;HUANG Shaobin;BAI Jian;LUO Shuntian(Department of General Surgery,Changsha Central Hospital,University of South China,Changsha 410018,P.R.China;Department of General Surgery,Zhongshan Chenxinghai Hospital,Zhongshan,Guangdong 528415,P.R.China)

机构地区：[1]南华大学附属长沙市中心医院普外科,长沙410018 [2]广东省中山陈星海医院普外科,广东中山528415

出　　处：《中国普外基础与临床杂志》2022年第3期415-420,共6页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的总结可变剪接在胰腺癌中的研究进展,为进一步研究提供参考。方法检索可变剪接在胰腺癌的基础和临床研究相关文献并加以综述。结果可变剪接调节异常可改变基因的表达水平或产生新的剪切异构体,从而影响胰腺癌的发生、进展或化学治疗耐药。差异表达的剪接异构体可能作为胰腺癌诊断、侵袭性和预后预测的标志物。结论进一步探索可变剪接在胰腺癌发生发展中的分子机制,是改善胰腺癌早期诊断和治疗的新思路。Objective To summarize the research progress of alternative splicing in pancreatic cancer,and to provide reference for further research.Method The experimental and clinical studies of alternative splicing in pancreatic cancer were reviewed.Results Alternative splicing dysregulation resulted in changed gene expression or novel isoform formation,thereby influencing the carcinogenesis,progression or chemoresistance of pancreatic cancer.The differentially expressed alternative splicing isoforms may serve as diagnostic markers,indicators of aggressiveness or prognostic markers of pancreatic cancer.Conclusion Further investigation of the molecular mechanisms of alternative splicing in carcinogenesis and progression of pancreatic cancer is a new way to improve the early diagnosis and treatment of pancreatic cancer.

关 键 词：胰腺癌 可变剪接 肿瘤发生 肿瘤进展 化学治疗耐药 

分 类 号：R735.9[医药卫生—肿瘤]